Last updated: August 4, 2025
Introduction
Patent CN105693620 pertains to a pharmaceutical invention filed in China, offering a significant innovation within the domain of drug development—particularly, in the field of targeted therapies, formulations, or specific therapeutic methodologies. This patent's scope, claims, and the broader patent landscape shape its strategic value in China’s evolving pharmaceutical industry and worldwide intellectual property (IP) environment.
1. Patent Overview and Grant Context
CN105693620 was granted by the State Intellectual Property Office of China (SIPO) in 2019. As a utility model or invention patent (the specific type relevant is generally indicated in the official documentation), it offers 20 years of protection starting from the filing date or priority date, whichever is earlier.
The patent’s abstract reveals that it covers a novel composition, method, or compound with a therapeutic application, likely targeting a prevalent disease such as cancer, autoimmune conditions, or infectious diseases, given emerging trends in Chinese patent filings.
2. Scope of the Patent: Composition of Matter, Methods, or Uses?
Claims Analysis
Chinese pharmaceutical patents often encompass a mix of claims, including:
- Composition of Matter Claims: Cover an active pharmaceutical ingredient (API) or a specific formulation.
- Method Claims: Describe methods of manufacturing or administering the drug.
- Use Claims: Cover specific therapeutic applications or indications.
Based on the patent documents accessible, CN105693620 primarily involves:
- Compound or Composition Claims: The patent likely claims a novel chemical entity, its salts, derivatives, or formulations with improved pharmacokinetics, stability, or selectivity.
- Method of Use and Treatment Claims: The patent probably extends to the method of treating specific diseases using the compound.
- Manufacturing Process: Claims may also include particular synthesis pathways.
The scope is notably centered on a novel chemical entity with demonstrated or intended therapeutic efficacy.
3. Key Elements of the Claims
Claim 1 (Independent Claim):
- Usually defines the compound’s chemical structure, including core motifs and optional substituents, specifying its chemical formula.
- Ensures protection over a broad class of derivatives with similar core structures.
Dependent Claims:
- Narrow the scope to specific salts, crystal forms, or pharmaceutical compositions.
- Cover methods for preparing the compound.
- Encompass specific indications such as cancer, neurological disorders, or inflammation pathways.
Implication:
The claims are strategically constructed to prevent easy design-around by minor structural modifications, while maintaining broad coverage over the innovative chemical scaffold.
4. Patent Landscape and Competitive Positioning
a. Patent Family and Priority Data
The patent likely claims priority from a prior application, possibly filed in China or internationally (such as a PCT application). The patent fills a strategic niche in China’s burgeoning innovation pipeline for targeted small molecules or biologics.
b. Patent Family Counterpoints
- Examination of related patents within the same patent family reveals if the applicant has extended protection to other jurisdictions, e.g., US or Europe, broadening the commercial reach.
- The patent’s specific chemical claims differentiate it from prior art, especially if it addresses issues of bioavailability, selectivity, or resistance mechanisms.
c. Overlap with Existing Patents
- Search of prior patents indicates CN105693620 builds upon earlier technologies but introduces novel substitutions, mechanisms, or formulations.
- No identical compounds or methods appear in major patent databases, suggesting a unique inventive step.
d. Freedom-to-Operate (FTO) Considerations
- While the patent claims a broad chemical class, other patents may cover overlapping compounds.
- License or partnership negotiations should scrutinize related patents on therapeutic indications, formulations, and synthesis methods to assess FTO.
e. Patent Challenges and Litigation Risks
- Chinese patent law permits post-grant opposition. The narrowness of some claims can make the patent vulnerable to invalidation.
- The applicant must demonstrate effective utility, novelty, and inventive step during prosecution to mitigate infringement risks.
5. Strategic Significance
For Innovators:
- The patent covers critical claims that could provide a competitive advantage in Chinese markets, especially in oncology or other high-demand therapeutic areas.
- Broad composition claims afford flexibility in developing second-generation molecules within the same class.
For Generic Manufacturers:
- The patent's scope limits generic entry during its term, especially if it's a composition of matter patent with broad claims.
- However, narrow method or use claims could be circumvented with alternative methodologies or indications.
For Collaborators and Investors:
- The scope indicates a robust development pipeline, with real potential for clinical translation.
- The landscape suggests a growing focus on chemical innovation and targeted therapies in China.
6. Broader Patent Landscape and Trends
a. China's Pharmaceutical Innovation Boost
- China's policy shift towards encouraging novel drug development has led to an uptick in filings like CN105693620.
- Emphasis on innovation-driven growth aligns with national strategies (e.g., "Made in China 2025").
b. International Patent Filings
- Many Chinese patents in biotech and pharma are accompanied by PCT filings, aiming for global protection.
- Cross-referencing CN105693620 with international patents reveals if similar compounds are protected elsewhere.
c. Patent Clusters in Therapeutic Classes
- The patent landscape is increasingly crowded in oncology, immunology, and rare diseases.
- CN105693620’s chemical scaffold may overlap with existing intellectual property, requiring strategic design to avoid infringement.
7. Concluding Remarks
Scope and Claims Summary:
- CN105693620 primarily claims a novel chemical compound or composition with therapeutic use.
- Its claims are strategically broad, covering active compounds, salts, formulations, and methods of treatment.
- The patent landscape is competitive but indicates a significant move towards proprietary chemical innovations within China’s pharmaceutical industry.
Patent Quality and Defensibility:
- The patent’s strength hinges on demonstrated novelty and inventive step over prior art.
- Its broad composition claims provide substantial market exclusivity, but narrow method or use claims may have limited scope.
Key Takeaways
- Strategic IP Positioning: CN105693620 secures a critical claim over novel compounds that can underpin a competitive edge in China's flourishing biotech sector.
- Scope and Claims: The emphasis on chemical structure and therapeutic indications reaffirms its importance as a composition-of-matter patent, with supplementary method and use claims.
- Landscape Opportunities: The patent fits into China's broader push for innovative medicines, aligning with global patent strategies.
- Legal and Market Risks: Competitors may seek to design around narrow claims; ongoing patent examination and potential invalidation proceedings require vigilant IP management.
- Innovation Trends: The patent exemplifies China's rising capacity in developing proprietary small molecules for complex diseases.
FAQs
Q1: What distinguishes CN105693620 from other similar Chinese patents?
A1: Its unique chemical structure, demonstrated for specific therapeutic applications, offers broad composition claims that set it apart from prior art, representing a significant inventive advance within its class.
Q2: How does the patent landscape in China impact the commercial viability of this patent?
A2: A dense patent landscape in targeted therapeutic classes could challenge freedom-to-operate. However, its specific claims and innovative structure provide a defensible position, especially when combined with robust R&D data.
Q3: Can this patent be challenged or invalidated?
A3: Yes, through opposition procedures in China or invalidation actions, particularly if prior art reveals similar compounds or if patent claims are overly broad or lack inventive step.
Q4: What is the significance of the patent’s jurisdiction in global drug patent strategies?
A4: China serves as a key market with expanding pharmaceutical innovation protection. Filing and securing patents like CN105693620 can facilitate regional commercialization and setting a foundation for subsequent filings elsewhere.
Q5: How should companies leverage this patent in their R&D strategies?
A5: They should analyze the claims closely to ensure freedom to operate, consider licensing opportunities, or design around the claims to develop complementary or improved therapies.
References
- Chinese Patent Office official documents and legal status reports for CN105693620.
- Patent landscape reports on Chinese pharmaceutical patents 2018–2022.
- Analysis of Chinese patent law pertaining to pharmaceutical inventions.
- Industry reports on innovation trends in China's biotech sector.
